

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM843080

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Security Interest in Trademarks recorded at R/F 7490/0655		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
JPMorgan Chase Bank, N.A., as Successor Collateral Agent		09/28/2023	National Banking Association: UNITED STATES
RECEIVING PARTY DATA			
Name:	Caerus Marketing Group, LLC		
Street Address:	3605 W. MacArthur Blvd.		
City:	Santa Ana		
State/Country:	CALIFORNIA		
Postal Code:	92704		
Entity Type:	Limited Liability Company: CALIFORNIA		
Name:	RxDataScience, Inc.		
Street Address:	45 Broadway		
City:	New York		
State/Country:	NEW YORK		
Postal Code:	10006		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 11			
Property Type	Number	Word Mark	
Registration Number:	5471274	RXDATASCIENCE	
Registration Number:	5527813	RXDS	
Registration Number:	5698180	RXDATASCIENCE	
Registration Number:	5704067	RXDS	
Registration Number:	5522492	RXDS INSIDE	
Registration Number:	5509770	RXDS INSIDE	
Registration Number:	5509769	RXDS	
Registration Number:	5471245	RXDATASCIENCE	
Registration Number:	5401630	STUDYKIK	
Registration Number:	5412454	STUDYKIK	
Registration Number:	5411471	STUDYKIK	
CORRESPONDENCE DATA			

CH \$290.00 5471274

Fax Number: 2127514864

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2129061216

Email: angela.amaru@lw.com

Correspondent Name: Latham & Watkins LLP c/o Angela M. Amaru

Address Line 1: 1271 Avenue of the Americas

Address Line 4: New York, NEW YORK 10020

ATTORNEY DOCKET NUMBER:	063808-0054
--------------------------------	-------------

NAME OF SUBMITTER:	Angela M. Amaru
---------------------------	-----------------

SIGNATURE:	/s/Angela M. Amaru
-------------------	--------------------

DATE SIGNED:	09/30/2023
---------------------	------------

Total Attachments: 12

source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page1.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page2.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page3.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page4.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page5.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page6.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page7.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page8.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page9.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page10.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page11.tif
source=Syneos - Affidavit to Confirm Release of Security Interest Executed#page12.tif

**AFFIDAVIT TO CONFIRM RELEASE OF SECURITY INTEREST
RECORDED AT REEL 7490, FRAME 0655**


I, Sara Epstein, do hereby declare as follows:

1. I am a Director of Caerus Marketing Group, LLC and RxDataScience, Inc., each a “Grantor” under the Intellectual Property Security Agreement dated as of November 10, 2021. I have personal knowledge of the facts stated herein and, if called as a witness, could and would testify competently to the matters set forth below.
2. Caerus Marketing Group, LLC and RxDataScience, Inc. are the owners of the trademark registrations as indicated on Exhibit A to this Affidavit (the “Trademarks”).
3. Pursuant to (a) the Pledge and Security Agreement, dated as of August 1, 2017 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”) and (b) the Intellectual Property Security Agreement dated as of November 10, 2021 and recorded in the United States Patent and Trademark Office on November 10, 2021 at Reel 7490, Frame 0655 (the “Intellectual Property Security Agreement”), each of Caerus Marketing Group, LLC and RxDataScience, Inc. granted to the Collateral Agent (as defined therein) a security interest in all right, title or interest of Caerus Marketing Group, LLC and RxDataScience, Inc.. as applicable, in, to or under the Trademarks.
4. Pursuant to the Successor Agent Agreement, dated as of March 26, 2019, JPMorgan Chase Bank, N.A. is the successor collateral agent to Credit Suisse AG.
5. The Intellectual Property Security Agreement inadvertently stated Credit Suisse AG and not JPMorgan Chase Bank, N.A. as “Collateral Agent.”
6. Caerus Marketing Group, LLC, RxDataScience, Inc. and JPMorgan Chase Bank, N.A. attempted to correct the record at the United States Patent and Trademark Office and filed a “corrected” Intellectual Property Security Agreement in favor of JPMorgan Chase Bank, N.A.
7. The “corrected” Intellectual Property Security Agreement was not accepted nor recorded by the United States Patent and Trademark Office
8. Nonetheless, the security interest granted pursuant to the Security Agreement and Intellectual Property Security Agreement was granted in favor of JPMorgan Chase Bank, N.A., as successor collateral agent.
9. The security interest granted pursuant to the Security Agreement and Intellectual Property Security Agreement has been released and JPMorgan Chase Bank, N.A. executed and delivered to Caerus Marketing Group, LLC and RxDataScience, Inc. a Release of Security Interest in Trademarks to evidence the release of such security interest (the “Release”).
10. Attached as Exhibit B to this Affidavit is a copy of the Release.

The undersigned, being hereby advised that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and that such willful false statements may jeopardize the validity of the application or any resulting registration, declares that the facts set forth herein are true; all statements made of her own knowledge are true; and all statements made on information and belief are believed to be true.

RxDataScience, Inc.

Caerus Marketing Group, LLC

By: 
Sara Epstein
Director


By: 
Sara Epstein
Director

EXHIBIT A**Trademarks**

OWNER	REGISTRATION NO. REGISTRATION DATE	TRADEMARK
RxDataScience, Inc.	5471274 5/15/2018	RXDATASCIENCE
RxDataScience, Inc.	5527813 7/13/2018	RXDS
RxDataScience, Inc.	5698180 3/12/2019	RXDATASCIENCE
RxDataScience, Inc.	5704067 3/19/2018	RXDS
RxDataScience, Inc.	5522492 7/24/2018	RXDS INSIDE
RxDataScience, Inc.	5509770 7/3/2018	RXDS INSIDE
RxDataScience, Inc.	5509769 7/3/2018	RXDS
RxDataScience, Inc.	5471245 5/15/2018	RXDATASCIENCE
Caerus Marketing Group, LLC	5401630 2/13/2018	STUDYKIK
Caerus Marketing Group, LLC	5412454 2/27/2018	STUDYKIK
Caerus Marketing Group, LLC	5411471 2/27/2018	STUDYKIK

EXHIBIT B

Release

See attached

RELEASE OF SECURITY INTEREST IN TRADEMARKS

This RELEASE OF SECURITY INTEREST IN TRADEMARKS (this “Release”), is dated as of September 28, 2023, and is made by JPMORGAN CHASE BANK, N.A., as administrative agent and collateral agent (in such capacities, the “Collateral Agent”) for the ratable benefit of the Secured Parties, in favor of the grantors listed on Schedule A hereto (the “Grantors”). Capitalized terms used but not otherwise defined herein have the meanings given to such terms (whether directly or by reference to another agreement or document) in the Security Agreement (as defined below).

WHEREAS, the Grantors and the Collateral Agent are party to that certain Pledge and Security Agreement, dated as of August 1, 2017 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time and in effect on the date hereof, the “Security Agreement”);

WHEREAS, pursuant to the Security Agreement, certain of the Grantors executed and delivered to the Collateral Agent (i) that certain Intellectual Property Security Agreement dated as of August 1, 2017 (the “2017 IP Security Agreement”), (ii) that certain Intellectual Property Security Agreement dated as of March 1, 2018 (the “2018 IP Security Agreement”), (iii) that certain Intellectual Property Security Agreement dated as of May 7, 2021 (the “May 2021 IP Security Agreement”), (iv) that certain Intellectual Property Security Agreement dated as of November 10, 2021 (the “November 2021 IP Security Agreement”), (v) that certain Intellectual Property Security Agreement Supplement dated as of December 19, 2022 (the “2022 Syneos IP Security Agreement Supplement”) and (vi) that certain Intellectual Property Security Agreement Supplement dated as of December 19, 2022 (the “2022 Synteract IP Security Agreement Supplement”, and together with the 2017 IP Security Agreement, the 2018 IP Security Agreement, the May 2021 IP Security Agreement, the November 2021 IP Security Agreement, and the 2022 Syneos IP Security Agreement Supplement, the “IP Security Agreements”);

WHEREAS, pursuant to the Security Agreement and the IP Security Agreements, each Grantor (as applicable) pledged, collaterally assigned, mortgaged, transferred and granted to the Collateral Agent its successors and permitted assigns, on behalf of and for the ratable benefit of the Secured Parties a continuing security interest in, among other collateral, all of such Grantor’s right, title and interest in, to and under all Trademarks, including the Trademark registrations and applications listed on Schedule B hereto, and all proceeds of the foregoing (collectively, the “Trademark Collateral”);

WHEREAS, the 2017 IP Security Agreement was recorded at the United States Patent and Trademark Office on September 1, 2017 at Reel 6145, Frame 0562;

WHEREAS, the 2018 IP Security Agreement was recorded at the United States Patent and Trademark Office on March 26, 2019 at Reel 6601, Frame 0037;

WHEREAS, the security interest in the Trademark Collateral pledged, collaterally assigned, mortgaged, transferred and granted under the Security Agreement, the 2017 IP Security Agreement and the 2018 IP Security Agreement was assigned to Collateral Agent (as successor to the original collateral agent) pursuant to the Successor Agent Agreement, dated as of March 26, 2019 and the Assignment of Security Interest in Intellectual Property, effective as of March 26, 2019 (the “Assignment”), and the Assignment was recorded at the United States Patent and Trademark Office on March 26, 2019 at Reel 6601, Frame 0048;

WHEREAS, the May 2021 IP Security Agreement was recorded at the United States Patent and Trademark Office on May 7, 2021 at Reel 7285, Frame 0245;

WHEREAS, the November 2021 IP Security Agreement was recorded at the United States Patent and Trademark Office on November, 10, 2021 at Reel 7490, Frame 0655;

WHEREAS, the 2022 Syneos IP Security Agreement Supplement was recorded at the United States Patent and Trademark Office on December 19, 2022 at Reel 7993, Frame 0289;

WHEREAS, the 2022 Synteract IP Security Agreement Supplement was recorded at the United States Patent and Trademark Office on December 19, 2022 at Reel 7993, Frame 0298; and

WHEREAS, the Collateral Agent now desires to terminate and release the IP Security Agreements and the entirety of its security interest in all of the Trademark Collateral.


NOW, THEREFORE, for good and valuable consideration (including the complete payment and performance of all Secured Obligations), the receipt and sufficiency of which are hereby acknowledged, and upon the terms set forth in this Release, the Collateral Agent hereby agrees as follows:

1. *Release.* The Collateral Agent (on behalf of itself and the other Secured Parties), at the Grantors' sole cost and expense, hereby (a) terminates, cancels, releases, relinquishes, and discharges its security interest in the Trademark Collateral, the goodwill of the business symbolized by the trademarks and the applications and registrations thereof, and all proceeds thereof, and (b) reassigns to each Grantor (as applicable), in its entirety, for the benefit of such Grantor and its successors and assigns, any and all right, title or interest the Collateral Agent or any of the other Secured Parties may have in, to or under the Trademark Collateral. Any and all right, title and interest of the Collateral Agent in, to and under the Trademark Collateral shall hereby be terminated, cancelled, released, relinquished and discharged. The Collateral Agent hereby authorizes each Grantor and its successors, assigns or other legal representatives to file this Release with the United States Patent and Trademark Office, and/or otherwise record or file this Release with the applicable government office or agency, at the sole expense of such Grantor, to evidence and effectuate the release and termination of the Collateral Agent's security interest in the Trademark Collateral. Collateral Agent further agrees to execute and deliver to Grantors, or each Grantor, any and all further documents and instruments, and do any and all further acts which Grantors (or their agents or designees) reasonably requests (at Grantors' sole cost and expense) in order to confirm, effectuate or record this Release and each Grantor's rights, title and interest in, to and under the Trademark Collateral.
2. *Governing Law.* This Release shall be governed by, and construed in accordance with, the laws of the State of New York.
3. *Waiver of Jury Trial.* EACH PARTY TO THIS RELEASE HEREBY EXPRESSLY WAIVES ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING UNDER THIS RELEASE OR IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO OR ANY OF THEM WITH RESPECT TO THIS RELEASE, OR THE TRANSACTIONS RELATED THERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER FOUNDED IN CONTRACT OR TORT OR OTHERWISE; AND EACH PARTY HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY.

[Signature page follows]

IN WITNESS WHEREOF, the Collateral Agent has caused this Release to be executed by its duly authorized representative as of the date first above written.

JPMORGAN CHASE BANK, N.A.,
as Collateral Agent

By: 
Name: Maurice Dattas
Title: Vice President

Schedule A

1. Addison Whitney LLC
2. BioSector 2 LLC
3. Syneos Health Consulting, Inc.
4. Chandler Chicco Agency, L.L.C.
5. Gerbig, Snell/Weisheimer Advertising, LLC
6. Syneos Health Communications, Inc.
7. Syneos Health US, Inc.
8. Syneos Health Clinical, Inc.
9. The Selva Group, LLC
10. Syneos Health, LLC
11. Taylor Strategy Partners, LLC
12. Synteract, Inc.
13. RxDataScience, Inc.
14. Caerus Marketing Group, LLC

Schedule B

2017 IP Security Agreement recorded at Reel/Frame 6145/0562 and assigned at 6601/0048 (March 2019)

OWNER	REG. NO.	TRADEMARK
Addison Whitney LLC (f/k/a AW Acquisition LLC)	Registration No. 2,328,427	ADDISON WHITNEY®
BioSector 2 LLC	Registration No. 2,771,189	BIOSECTOR 2
Syneos Health Communications, Inc. (f/k/a inVentiv Health Communications, Inc., the successor by merger to Blue Diesel, LLC)	Registration No. 2,749,759	BLUE DIESEL
Syneos Health Consulting, Inc. (f/k/a inVentiv Health Consulting, Inc.)	Registration No. 3,498,271	LAUNCH PLAYBOOK
Syneos Health Consulting, Inc. (f/k/a inVentiv Health Consulting, Inc.)	Registration No. 3,644,785	WINNING LABEL
Chandler Chicco Agency, L.L.C.	Registration No. 3,664,858	ALLIDURA
Gerbig, Snell/Weisheimer Advertising, LLC	Registration No. 2,997,802	GSW WORLDWIDE
Gerbig, Snell/Weisheimer Advertising, LLC	Registration No. 2,995,150	GSW
Syneos Health Communications, Inc. (f/k/a inVentiv Health Communications, Inc.)	Registration No. 2,977,610	CADENT MEDICAL COMMUNICATIONS
Syneos Health Communications, Inc. (f/k/a inVentiv Health Communications, Inc.)	Registration No. 2,868,928	GERBIG, SNELL/WEISHEIMER
Syneos Health US, Inc. (f/k/a inVentiv Health, Inc.)	Registration No. 3,331,958	INVENTIV HEALTH
Syneos Health US, Inc. (f/k/a inVentiv Health, Inc.)	Registration No. 4,319,608	INVENTIV THERAPEUTICS INSTITUTE
Syneos Health US, Inc. (f/k/a inVentiv Health, Inc.)	Registration No. 4,678,437	PALIO+IGNITE
Syneos Health Clinical, Inc. (f/k/a inVentiv Health Clinical, Inc.)	Registration No. 3,011,364	SYNERGO BE WELL. WORK BETTER
The Selva Group, LLC	Registration No. 3,176,842	THE SELVA GROUP
Syneos Health, LLC (f/k/a INC Research, LLC)	Registration No. 2,922,548	INC RESEARCH
Syneos Health, LLC (f/k/a INC Research, LLC)	Registration No. 3,435,125	PLANACTIVATION
Syneos Health, LLC (f/k/a INC Research, LLC)	Registration No. 3,435,126	PROGRAMACCELERATE

OWNER	REG. NO.	TRADEMARK
Syneos Health, LLC (f/k/a INC Research, LLC)	Registration No. 3,435,129	QUALITYFINISH
Syneos Health, LLC (f/k/a INC Research, LLC)	Registration No. 3,435,127	QUICKSTART
Syneos Health, LLC (f/k/a INC Research, LLC)	Registration No. 3,435,124	THE TRUSTED PROCESS
Syneos Health US, Inc. (f/k/a inVentiv Health, Inc.)	Application No. 87/440,090 5457068	CHAMBERLAIN HEALTHCARE PUBLIC RELATIONS
Syneos Health US, Inc. (f/k/a inVentiv Health, Inc.)	Application No. 87/440,103 5911542	CHANDLER CHICCO AGENCY
Syneos Health US, Inc. (f/k/a inVentiv Health, Inc.)	Application No. 87/406,693 5316995	NAVICOR
Syneos Health US, Inc. (f/k/a inVentiv Health, Inc.)	Application No. 87/406,778 5316997	NAVICOR INVENTIV HEALTH (& DESIGN) STACKED
Syneos Health US, Inc. (f/k/a inVentiv Health, Inc.)	Application No. 87/406,808 5456882	NAVICOR THE ONCOLOGY AGENCY
Syneos Health US, Inc. (f/k/a inVentiv Health, Inc.)	Application No. 87/394,701 5394540	SHORTENING THE DISTANCE FROM LAB TO LIFE
Syneos Health, LLC (f/k/a INC Research, LLC)	Application No. 87/124,101 5272622	CULTURE OF OPPORTUNITY

2018 IP Security Agreement recorded at Reel/Frame 6601/0037 and assigned at 6601/0048 (March 2019)

OWNER	REG. NO.	TRADEMARK
Taylor Strategy Partners, LLC	Registration No. 4,305,621	TAYLOR STRATEGY PARTNERS
Taylor Strategy Partners, LLC	Registration No. 4,305,632	TSP TAYLOR STRATEGY PARTNERS

May 2021 IP Security Agreement recorded at Reel/Frame 7285/0245

MARK	App #	REG. #	OWNER
BRINGING CLINICAL TRIALS TO LIFE	90/041330	6265650	Syneract, Inc.
INTELLIGENT CLINICAL DEVELOPMENT	86/098375	4698117	Syneract, Inc.
KINDER PHARM & Design (In Color)	86/268843	4941924	Syneract, Inc.
PKPD BIOSCIENCE & Design (In Color)	86/273839	4754475	Syneract, Inc.
S Design	87/880322	5777077	Syneract, Inc.
S Design	90/504631		Syneract, Inc.
S Stylized	78/186147	2771811	Syneract, Inc.
S Stylized & Oval Design	87/020843	5100116	Syneract, Inc.
SYNTERACT	78/082226	2673314	Syneract, Inc.
SYNTERACT	90/504612		Syneract, Inc.
SYNTERACTHCR	87/175409	5190548	Syneract, Inc.

November 2021 IP Security Agreement recorded at Reel/Frame 7490/0655

OWNER	REG. NO.	TRADEMARK
RxDataScience, Inc.	5471274 5/15/2018	RXDATASCIENCE
RxDataScience, Inc.	5527813 7/13/2018	RXDS
RxDataScience, Inc.	5698180 3/12/2019	RXDATASCIENCE
RxDataScience, Inc.	5704067 3/19/2018	RXDS
RxDataScience, Inc.	5522492 7/24/2018	RXDS INSIDE
RxDataScience, Inc.	5509770 7/3/2018	RXDS INSIDE
RxDataScience, Inc.	5509769 7/3/2018	RXDS
RxDataScience, Inc.	5471245 5/15/2018	RXDATASCIENCE


OWNER	REG. NO.	TRADEMARK
Caerus Marketing Group, LLC	5401630 2/13/2018	STUDYKIK
Caerus Marketing Group, LLC	5412454 2/27/2018	STUDYKIK
Caerus Marketing Group, LLC	5411471 2/27/2018	STUDYKIK

2022 Synteract IP Security Agreement Supplement recorded at Reel/Frame 7993/0298

MARK	APP. #	REG. #	OWNER
SYNTERACT	90504612	6595078	Synteract, Inc.
S	90504631	6595080	Synteract, Inc.

2022 Syneos IP Security Agreement Supplement recorded at Reel/Frame 7993/0289

MARK	APP. #	REG. #	OWNER
<i>Design Only</i> 	97389752 29-APR-2022	---	Syneos Health, LLC
SYNEOS HEALTH	90702195 11-MAY-2021	6686548 29-MAR-2022	Syneos Health, LLC
SPHERICO	90493177 27-JAN-2021	6564420 16-NOV-2021	Syneos Health, LLC
SYNEOS ONE	88679042 04-NOV-2019	6068869 02-JUN-2020	Syneos Health, LLC
PATIENTPULSE 	88470549 12-JUN-2019	6273546 16-FEB-2021	Syneos Health, LLC
DYNAMIC ASSEMBLY	88450697 29-MAY-2019	5975600 04-FEB-2020	Syneos Health, LLC
BIOPHARMACEUTIC AL ACCELERATION MODEL	88428831 14-MAY-2019	6093742 07-JUL-2020	Syneos Health, LLC
BAM	88428843 14-MAY-2019	6161365 29-SEP-2020	Syneos Health, LLC

MARK	APP. #	REG. #	OWNER
PRERISK	88342306 15-MAR-2019	6267294 09-FEB-2021	Syneos Health, LLC
SPEAK PEOPLE 	88136353 28-SEP-2018	5750795 14-MAY-2019	Syneos Health, LLC
SPEAK PEOPLE	88136359 28-SEP-2018	5750796 14-MAY-2019	Syneos Health, LLC
CADENT MEDICAL COMMUNICATIONS	87784825 05-FEB-2018	5731076 23-APR-2019	Syneos Health US, Inc.
SYNEOS HEALTH 	87717521 12-DEC-2017	5814321 23-JUL-2019	Syneos Health, LLC